Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Dec;33(12):2118–2125. doi: 10.1128/aac.33.12.2118

In vitro and in vivo activities of piritetrate (M-732), a new antidermatophytic thiocarbamate.

K Iwata 1, T Yamashita 1, H Uehara 1
PMCID: PMC172832  PMID: 2619275

Abstract

Piritetrate (M-732), a new topical antifungal agent belonging chemically to the thiocarbamates, was demonstrated to possess a potent selective antidermatophytic activity. In terms of its MICs in susceptibility testing, mainly done by using Sabouraud dextrose agar plates, piritetrate exhibited several- to 10-fold-stronger antidermatophytic activity than tolnaftate, a reference thiocarbamate. Furthermore, piritetrate was found to show a broader antifungal spectrum than tolnaftate; relatively many species and strains of dematiaceous fungi, dimorphic fungi, and some other filamentous fungi as well as a few strains of Cryptococcus neoformans were fairly susceptible to piritetrate, while almost all the tested species and strains were resistant to tolnaftate. All the tested species of the genus Candida were, however, resistant to both compounds. Variables which can influence antimicrobial activity caused few changes in the MICs of either compound against Trichophyton mentagrophytes; however, an increase in the inoculum size resulted in a significant increase in the MICs. The antidermatophytic activities of piritetrate and tolnaftate were fungistatic but not fungicidal. Piritetrate also exhibited a more potent in vitro anti-T. mentagrophytes activity than clotrimazole or tolciclate. Piritetrate and tolnaftate had no antibacterial activity. The in vivo activity of topically administered piritetrate against experimental dermal infection of guinea pigs with T. mentagrophytes was more effective than that of tolnaftate both mycologically and clinically. Piritetrate manifested no acute toxicity in laboratory animals when administered even in large quantities by the oral, intraperitoneal, and topical routes.

Full text

PDF
2118

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amsel L. P., Cravitz L., VanderWyk R., Zahry S. Comparison of in vitro activity of undecylenic acid and tolnaftate against athlete's foot fungi. J Pharm Sci. 1979 Mar;68(3):384–385. doi: 10.1002/jps.2600680338. [DOI] [PubMed] [Google Scholar]
  2. Bianchi A., Monti G., de Carneri I. Tolciclate: further antimycotic studies. Antimicrob Agents Chemother. 1977 Sep;12(3):429–430. doi: 10.1128/aac.12.3.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Carneri I., Monti G., Bianchi A., Castellino S., Meinardi G., Mandelli V. Tolciclate against dermatophytes. Arzneimittelforschung. 1976;26(5):769–772. [PubMed] [Google Scholar]
  4. Hantschke D., Reichenberger M. Doppelblinde, randomisierte vergleichende in vivo Untersuchungen zwischen den Antimykotika Clotrimazol, Tolnaftat und Naftifin. Mykosen. 1980 Dec;23(12):657–668. [PubMed] [Google Scholar]
  5. Hashimoto Y., Noguchi T., Kitagawa H., Ohta G. Toxicologic and pharmacologic properties of tolnaftate, an antitrichophyton agent. Toxicol Appl Pharmacol. 1966 May;8(3):380–385. doi: 10.1016/0041-008x(66)90048-2. [DOI] [PubMed] [Google Scholar]
  6. Jacob Z., Wahab S., Ghosh M., Srivastava O. P. Superficial mycoses and in vitro sensitivity of dermatophytes and Candida species to tolciclate and clotrimazole. Indian J Med Res. 1981 Sep;74:365–371. [PubMed] [Google Scholar]
  7. Loebenberg D., Parmegiani R., Hanks M., Waitz J. A. Comparative in vitro and in vivo antifungal activity of tolnaftate and various undecylenates. J Pharm Sci. 1980 Jun;69(6):739–741. doi: 10.1002/jps.2600690638. [DOI] [PubMed] [Google Scholar]
  8. Morita T., Iwata K., Nozawa Y. Inhibitory effect of a new mycotic agent, piritetrate on ergosterol biosynthesis in pathogenic fungi. J Med Vet Mycol. 1989;27(1):17–25. doi: 10.1080/02681218980000031. [DOI] [PubMed] [Google Scholar]
  9. Noguchi T., Hashimoto Y., Makita T., Tanimura T. Teratogenesis study of tolnaftate, an antitrichophyton agent. Toxicol Appl Pharmacol. 1966 May;8(3):386–397. doi: 10.1016/0041-008x(66)90049-4. [DOI] [PubMed] [Google Scholar]
  10. ROBINSON H. M., Jr, RASKIN J. TOLNAFTATE THERAPY OF MYCOTIC INFECTIONS. PRELIMINARY REPORT. J Invest Dermatol. 1964 Feb;42:185–187. doi: 10.1038/jid.1964.40. [DOI] [PubMed] [Google Scholar]
  11. Shadomy S. In vitro antifungal activity of clotrimazole (Bay b 5097). Infect Immun. 1971 Aug;4(2):143–148. doi: 10.1128/iai.4.2.143-148.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Srivastava O. P., Chandra B., Mathur I. S., Gupta H. P. Experimental ringworm infection in guineapig for the evaluation of drugs. Indian J Exp Biol. 1978 Jun;16(6):700–701. [PubMed] [Google Scholar]
  13. Wahab S., Srivastava O. P., Singh N. B., Gupta S. K. Comparative in vitro & in vivo evaluation of tolciclate, tolnaftate, miconazole, clotrimazole & undecylenic acid against Trichophyton mentagrophytes. Indian J Exp Biol. 1978 Nov;16(11):1200–1202. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES